Literature DB >> 8732268

The longitudinal muscle of rat ileum as a sensitive monoreceptor assay for bradykinin B1 receptors.

S Meini1, A Lecci, C A Maggi.   

Abstract

1. Various bradykinin derivatives, acting preferentially at B1 or B2 receptors, were tested in the isolated longitudinal smooth muscle of rat ileum. Experiments were carried out in the presence of chlorpheniramine and atropine (both 1 microM), guanethidine and indomethacin (both 3 microM) and of the peptidase inhibitors (captopril, bestatin and thiorphan, all 1 microM). 2. The rank order of potency was (pD2 values +/- s.e.mean, n = 5 in parentheses, at 5 h from set-up): [des-Arg9]-BK (8.27 +/- 0.11) > or = [des-Arg10]-kallidin (7.67 +/- 0.24) > bradykinin (6.69 +/- 0.25). The B2 receptor selective agonist, [Hyp3,Tyr(Me)8]-BK, was approximately 10 fold less active than bradykinin. Contractile responses to all agonists increased with time. The maximal response to the B1 receptor agonist, [desArg9]-BK at 5 h (94 +/- 2%) was significantly (P < 0.05) greater than that measured at 2 h (74 +/- 2%). 3. The B2 receptor antagonist, D-Arg[Hyp3, Thi5, D-Tic7, Oic8]-BK (Hoe 140, 0.1 microM) did not affect responses to the B1 receptor agonist [des-Arg9]-BK (0.1 nM--1 microM) nor those to the B2 receptor agonist, [Hyp3,Tyr(Me)8]-BK (1 nM--10 microM). In control experiments performed in the longitudinal smooth muscle of guinea-pig ileum and rat isolated urinary bladder as bioassays for B2 receptors, the B2 receptor antagonist Hoe 140 (0.1 microM) antagonized bradykinin-induced contractions. 4. In the rat isolated ileum the B1 receptor antagonist, D-Arg[Hyp3, Thi5, D-Tic7, Oic8, des-Arg9]-BK ([des-Arg10]-Hoe 140, 0.3 - 10 microM) competitively antagonized contractile responses to [des-Arg9]-BK with an estimated pKB of 6.74 +/- 0.08 (Schild plot slope with confidence limits 1.22, (0.70 - 1.73) n = 13). In control experiments in the guinea-pig isolated ileum and rat isolated urinary bladder, [des-Arg10]-Hoe 140 (1 - 10 microM) did not inhibit B2 receptor-mediated contractile responses. 5. The putative B1 receptor antagonist, [Leu8,des-Arg9]-BK, behaved as a partial agonist when responses were determined 2 h from set-up (pD2 6.43 +/- 0.21, n = 5; Emax 30% of that evoked by [des-Arg9]-BK); at 5 h from set-up it behaved as a full agonist (pD2 7.48 +/- 0.12, n = 5; Emax 90% of that evoked by [des-Arg9]-BK). At this time the response to [Leu8,des-Arg9]-BK was antagonized in a concentration-dependent manner by [des-Arg10]-Hoe 140, which at 1 microM and 10 microM, produced dose-ratios of 6.33 +/- 3.66 (n = 4) and 103 +/- 40 (n = 4). 6. In view of the rank order of potency of agonists, the antagonist activity by [des-Arg10]-Hoe 140 and the lack of antagonist activity of Hoe 140, we conclude that the longitudinal smooth muscle of rat ileum, after histamine, acetylcholine, noradrenaline, and prostanoid production blockade, is a sensitive monoreceptor assay for studying the pharmacology of bradykinin B1 receptors. Further the preparation can also be used as a sensitive bioassay to identify partial agonist activity of B1 receptor antagonists such as [Leu8,desArg9]-BK.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732268      PMCID: PMC1909556          DOI: 10.1111/j.1476-5381.1996.tb15331.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

Review 1.  Bradykinin receptors: pharmacological properties and biological roles.

Authors:  J M Hall
Journal:  Pharmacol Ther       Date:  1992-11       Impact factor: 12.310

2.  How we describe competitive antagonists: three questions of usage.

Authors:  D H Jenkinson
Journal:  Trends Pharmacol Sci       Date:  1991-02       Impact factor: 14.819

3.  DesArg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (desArg10-[Hoe140]) is a potent bradykinin B1 receptor antagonist.

Authors:  K Wirth; G Breipohl; J Stechl; J Knolle; S Henke; B Schölkens
Journal:  Eur J Pharmacol       Date:  1991-11-26       Impact factor: 4.432

4.  Induction of vascular smooth muscle bradykinin B1 receptors in vivo during antigen arthritis.

Authors:  S G Farmer; B A McMillan; S N Meeker; R M Burch
Journal:  Agents Actions       Date:  1991-09

Review 5.  Bradykinin and inflammatory pain.

Authors:  A Dray; M Perkins
Journal:  Trends Neurosci       Date:  1993-03       Impact factor: 13.837

6.  Induction of B1 receptors in vivo in a model of persistent inflammatory mechanical hyperalgesia in the rat.

Authors:  A J Davis; M N Perkins
Journal:  Neuropharmacology       Date:  1994-01       Impact factor: 5.250

7.  Induction of bradykinin B1 receptors in vivo in a model of ultra-violet irradiation-induced thermal hyperalgesia in the rat.

Authors:  M N Perkins; D Kelly
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Activity of peptide and non-peptide antagonists at peripheral NK1 receptors.

Authors:  R Patacchini; P Santicioli; M Astolfi; P Rovero; G Viti; C A Maggi
Journal:  Eur J Pharmacol       Date:  1992-04-29       Impact factor: 4.432

10.  Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor.

Authors:  J F Hess; J A Borkowski; G S Young; C D Strader; R W Ransom
Journal:  Biochem Biophys Res Commun       Date:  1992-04-15       Impact factor: 3.575

View more
  4 in total

1.  Comparative antagonist pharmacology at the native mouse bradykinin B2 receptor: radioligand binding and smooth muscle contractility studies.

Authors:  S Meini; P Cucchi; F Bellucci; C Catalani; S Giuliani; P Santicioli; C A Maggi
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

2.  Pharmacological and molecular evidence for kinin B1 receptor expression in urinary bladder of cyclophosphamide-treated rats.

Authors:  P Belichard; J M Luccarini; E Defrêne; P Faye; R M Franck; H Duclos; J L Paquet; D Pruneau
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

3.  In vitro and in vivo effects of kinin B(1) and B(2) receptor agonists and antagonists in inbred control and cardiomyopathic hamsters.

Authors:  S Hallé; F Gobeil; J Ouellette; C Lambert; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  Neuroprotective effect of kinin B1 receptor activation in acute cerebral ischemia in diabetic mice.

Authors:  Dorinne Desposito; Georges Zadigue; Christopher Taveau; Clovis Adam; François Alhenc-Gelas; Nadine Bouby; Ronan Roussel
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.